PAD4 is one of the most prominently investigated factors critical for NET formation, and PAD inhibitors have been extensively studied in the context of a broad variety of diseases, including multiple sclerosis [65], myocardial infarction [66], and rheumatoid arthritis [67]. This evidence concerns the gene PADI4 and myocardial infarction.